CAS number: 
53714-56-0 (net)
74381-53-6 (acetate)


Molecular formula: C59H84N16O12

Molecular weight: 1209.42 a.m.u.

Fields of Application
Prostate Cancer and breast Cancer
Endometriosis and central precocious puberty

Leuprolide is a synthetic polypeptide which acts as LH-RH (Luteinizing-hormone releasing hormone) analogue agonist. LH-RH is secreted in the hypothalamus and its release induces the secretion of LH (Luitenizing hormone) and FSH (Follicle-stimulating hormone) from the pituitary gland. These two hormones act on the ovaries and the testes and are responsible of the profertility effects of LHRH through the release of steroideal hormones. It is used to treat a number of medical problems, which include: anaemia caused by bleeding of uterine leiomyomas (tumours in the uterus), cancer of the prostate gland in men, central precocious puberty (CPP) and pain due to endometriosis in women.

When given regularly to men and boys, leuprolide decreases testosterone levels. When given regularly to women and girls, leuprolide decreases estrogens levels. By shrinking tumours in the uterus, leuprolide helps stop anaemia by decreasing the vaginal bleeding from these tumours. Iron supplements should be used to help treat the anaemia.

When given to boys and girls experiencing early puberty, leuprolide slows down the development of the genital areas in both sexes and breast development in girls. This medicine delays puberty in a child only as long as the child continues to receive it.

Suppressing estrogens can also cause thinning of the bones or slowing of their growth. This is a positive effect in girls and boys whose bones grow too fast when puberty begins too early.

Regular injectable form and Depot injectable form.